EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder

Brady D Greene, Adam Fijtman, Nefize Yalin, Mark D Kvarta, Philip R Wang, Mani Yavi, Dede Greenstein, Carlos A Zarate

Journal of Affective Disorders · 2026

DOI: 10.1016/j.jad.2025.120780 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Brady D Greene und 7 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Anhedonia, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: No clinically useful biomarkers currently predict antidepressant response to ketamine in treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD). This study investigated whether baseline thyroid-stimulating hormone (TSH) levels are associated with ketamine's antidepressant, anti-anhedonic, and anti-suicidal effects. METHODS: This was a secondary exploratory analysis of data drawn from four NIH-sponsored, randomized, placebo-controlled, double-blind crossover studies of ketamine in inpatients with current MDD (n = 39) or bipolar depression (n = 44). Baseline TSH levels were measured before the first intravenous saline or ketamine infusion (0.5 mg/kg). A two-week washout preceded the second infusion. Depression and anhedonia were measured with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Snaith-Hamilton Pleasure Scale, respectively. Suicidal ideation (SI) was measured as a weighted average of the Beck Depression Inventory and the MADRS suicide items. Linear mixed models were used to evaluate baseline TSH levels as a moderator of response to ketamine (versus placebo), controlling for thyroid disease, lithium use, and depression severity at 230 min and days 1, 2, and 7 post-infusion. RESULTS: In individuals with BD, higher baseline TSH levels were associated with greater decreases in the severity of depressive (drug*TSH, p < 0.0007) and anhedonia (drug*TSH, p < 0.0001) symptoms post-ketamine. TSH levels were not associated with changes in depression, anhedonia, or SI severity in MDD post-ketamine. CONCLUSION: Baseline TSH levels were associated with ketamine's antidepressant and anti-anhedonic effects in BD but not MDD. These findings suggest that TSH may serve as a predictive biomarker of response and highlight a potential thyroid-glutamate influence in ketamine's mechanism of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnhedoniaAntidepressive AgentsBipolar DisorderMajor Depressive DisorderDepressive Disorder, Treatment-ResistantKetamineThyrotropinAdultFemaleHumansMaleMiddle AgedCross-Over StudiesDouble-Blind MethodPsychiatric Status Rating ScalesSuicidal IdeationTreatment OutcomeSecondary Data Analysis

Stichwörter der Autor:innen

Bipolar depressionKetamineMajor depressive disorderThyroid-stimulating hormoneTreatment-resistant depression

Substanzen

Antidepressive AgentsKetamineThyrotropin

Autor:innen und Institutionen

  • Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
  • Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. Electronic address: adam.fijtman@nih.gov.

Förderung

  • Intramural NIH HHS
  • National Institutes of Health
  • National Institute of Mental Health

Zitieren

APA

Greene, B. D., Fijtman, A., Yalin, N., Kvarta, M. D., Wang, P. R., Yavi, M., Greenstein, D., & Zarate, C. A. (2026). Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120780

Vancouver

Greene BD, Fijtman A, Yalin N, Kvarta MD, Wang PR, Yavi M, et al. Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120780

BibTeX
@article{Greene2026,
  author = {Greene, Brady D and Fijtman, Adam and Yalin, Nefize and Kvarta, Mark D and Wang, Philip R and Yavi, Mani and Greenstein, Dede and Zarate, Carlos A},
  title = {Thyroid-stimulating hormone is associated with differential antidepressant and anti-anhedonic response to ketamine in bipolar depression but not major depressive disorder},
  journal = {Journal of Affective Disorders},
  year = {2026},
  doi = {10.1016/j.jad.2025.120780}
}
Kostenlos starten →